CEL-SCI Corporation (CVM) AI Stock Analysis

CEL-SCI Corporation, founded in 1983 and headquartered in Vienna, Virginia, develops immune-based therapies for cancer and infectious diseases. Its primary product candidate is Multikine, an investigational immunotherapy designed to stimulate the immune system against locally advanced primary squamous cell carcinoma of the head and neck, which has completed Phase 3 clinical trials. Additionally, the company is advancing its Ligand Epitope Antigen Presentation System (LEAPS) technology platform in pre-clinical studies to address conditions such as autoimmune diseases, infections, and allergies. The pipeline also includes CEL-2000 and CEL-4000, which are investigational candidates targeting rheumatoid arthritis.

Over its reported annual periods, CEL-SCI generated minimal and volatile revenue while incurring continuous operating losses. Annual revenue peaked at $558,664 in FY2020 after growing 20.7%, following revenue of $462,754 in FY2019 and $476,556 in FY2018. The company's five-year revenue compound annual growth rate from FY2015 to FY2020 was -3.2%. Net losses remained substantial due to research and development spending, reaching -$30.3M in FY2020 with research and development expense of $17.8M, compared to net income of -$24.7M in FY2019 and -$31.8M in FY2018. For the trailing twelve months ended June 30, 2026, revenue stood at $28,558, with quarterly revenue falling 62.7% year-over-year and diluted EPS at -$1.69.

As of June 30, 2026, CEL-SCI held $6.5M in cash and short-term investments against total debt of $7.9M, leaving net debt at $1.4M. Shareholders' equity was $11.0M out of total assets of $21.4M. The company reported a current ratio of 1.48 and a debt-to-equity ratio of 0.72. Operating cash flow remained negative across historical periods, including -$15.3M in FY2020 and -$16.3M in FY2019. In FY2025, capital expenditures were $38,109, while share issuance brought in $28.5M.

At a last closing price of $1.79 on October 16, 2026, CEL-SCI carries a market capitalization of $31.5M and an enterprise value of $30.9M. Because of minimal commercial revenue, its price-to-sales ratio stands at 92.9x, and its enterprise value-to-revenue ratio is 88.9x, both well above the median of its US-listed Healthcare peers of 4.1x price-to-sales. Its forward price-to-earnings ratio is 23.0x versus the peer median of 17.3x, while its EV-to-EBITDA multiple is 11.0x versus the peer median of 12.0x. Over the past year, CVM shares declined 81.4%, while the S&P 500 (SPY) returned 16.8%.

Wall Street coverage includes 1 analyst rating, categorized as Strong Buy, with 0 Buy, 0 Hold, 0 Sell, and 0 Strong Sell ratings. The mean price target is $12.50, representing an implied premium of 598.3% over the last close of $1.79. For the fiscal year ending September 30, 2026, the consensus expects revenue of $0 and EPS of -$3.07. For the following fiscal year, 1 analyst projects revenue of $6.0M and EPS of -$6.38. Over the last four quarters, the company delivered 1 EPS beat.

This page is an AI-written research summary of CEL-SCI Corporation (CVM). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: CVM income statement, CVM balance sheet, CVM key metrics, CVM analyst forecast, CVM chart. See the CVM stock overview for the latest quote and news.